What Zimmer Biomet's Quarter ended Sep 30, 2026 10-Q says: 6 signals
Zimmer Biomet filed its latest 10-Q with the SEC on Nov 4, 2026. It discusses capex increase, channel shift and cost reduction.
Public (ZBH)Medical Equipment Manufacturing10,000+ employeeszimmerbiomet.comLinkedIn
Get Zimmer Biomet's live signals in Claude or ChatGPT, or by API
What changed at Zimmer Biomet this week? Use Autobound signals for zimmerbiomet.com.- Filed
- Nov 4, 2026
- Period
- Quarter ended Sep 30, 2026
- Filings
- 3
- Signals
- 16
Source: Autobound Signal API · 80 signals tracked for Zimmer Biomet · updated
10-Q · latest 10
What Zimmer Biomet's 10-Q filings say
- SEC EDGAR
10-Q · Quarter ended Sep 30, 2026
Filed · 6 signals
Restructuring plans incur $146 million and $37 million toward targeted exit costs
Zimmer Biomet is executing the 2025 Restructuring Plan with expected pre-tax charges of $170 million by 2027, and a Manufacturing Network Optimization Plan with $60 million in expected exit costs by 2028.
$170M
total pre-tax charges for 2025 Restructuring Plan by end of 2027
A transition to a new platform distributor concentrated credit risk, with extended payment terms granted in installments through October 2027.
12%
share of consolidated accounts receivable from one customer
2025 Restructuring Plan targets $175 million reduction in annual pre-tax operating expenses by 2027
The company expects to reduce gross annual pre-tax operating expenses by $175 million relative to 2024 baseline expenses by the end of 2027.
$175M
reduction in gross annual pre-tax operating expenses relative to 2024 baseline
Global selling prices fell 0.7% in Q3 and nine-month periods of 2026
Global selling prices had a negative effect of 0.7 percent on sales, driven by pressure from hospitals, health systems, governmental cost containment, and volume discounts.
-0.7%
year-over-year effect of global selling prices on sales
Capital additions fund construction of new manufacturing facility in Costa Rica
Additions to property, plant, and equipment reflected optimization of manufacturing networks and the construction of a new manufacturing facility in Costa Rica.
Zimmer Biomet transitioned to a new platform distributor in a region, repurchasing inventory from an incumbent distributor and reselling it to the new distributor with extended installments.
- SEC EDGAR
10-Q · Quarter ended Jun 30, 2026
Filed · 6 signals
Acquired business and signed merger agreement with private company for $245 million initial cash
Subsequent to June 30, 2026, Zimmer Biomet acquired a business and signed a merger agreement with a separate privately held company for approximately $245 million initial cash consideration plus up to $210 million in contingent consideration.
$245M
initial cash consideration for post-period business acquisition and signed merger agreement
Zimmer Biomet incurred $147 million of an expected $155 million in pre-tax charges through June 30, 2026 under its 2025 Restructuring Plan, which targets $175 million in gross annual pre-tax operating expense reductions by the end of 2027.
$175M
gross annual pre-tax operating expense reduction relative to 2024 baseline
Restructuring plan incurs $147 million of expected $155 million in pre-tax charges through Q2 2026
The company incurred approximately $147 million of an anticipated $155 million in total pre-tax restructuring charges through June 30, 2026.
$155M
total expected pre-tax restructuring charges by end of 2027
International net sales rose 6.8 percent to $1,814.4 million in six-month period
International net sales reached $1,814.4 million for the six months ended June 30, 2026, representing a 6.8 percent year-over-year increase driven by bone cement, market growth, and foreign exchange benefits.
$1.8B
international net sales for the six months ended June 30, 2026
6.8%
increase in international net sales for the six-month period ended June 30, 2026
Earlier 10-Q filings
- 10-Q · Quarter ended Mar 31, 2026Filed · 4 signalsSEC EDGAR
Showing 10 of 16 filing signals. The Signal API returns all of them.
Get them with one API callEarnings calls
Zimmer Biomet earnings headlines
From earnings call transcripts (Signal API type earnings-transcripts).
| Call date | What the company said |
|---|---|
| Over 75% of U.S. sales force converted to dedicated modelThe company is 3 quarters into an 8-quarter initiative named Project Optima to transition to a specialized direct sales force. While generating short-term disruption in knees, rep turnover remains in the single digits as dedicated specialists are added across high-growth franchises. | |
| Expanded exclusive distribution and supply agreement with THINK SurgicalThe company entered into an extended multiyear distribution and supply agreement with THINK Surgical for an exclusive version of the wireless handheld TMINI robotic system compatible with Persona Knee. The platform targets outpatient settings and ambulatory surgery centers. | |
| Knee business declines 2.6% amid commercial disruption and market headwindsKnee segment sales contracted 2.6% on a constant currency basis, driven by a 2% decline in the U.S. and 3.4% internationally. Management attributed the U.S. drop to a sales force transition and stiff competition, alongside ongoing China distributor headwinds. | |
| Consolidating manufacturing footprint into Warsaw and lower-cost international sitesZimmer Biomet is closing select underutilized manufacturing plants and shifting domestic operations into multiple facilities in Warsaw, Indiana. Simultaneously, international manufacturing is shifting to lower-cost regions to address a 46% OpEx-to-sales ratio. | |
| Targeting 46% OpEx reduction via AI automation and India centerLeadership is seeking operating expense efficiency to reduce the 46% OpEx-to-sales ratio, targeting the $2.8 billion non-variable portion. Initiatives include partnering with AI implementation experts for transactional reengineering and scaling a global capability center in India. | |
| Adjusted gross margin down 90 bps to 71.7% on manufacturing costsGross margin declined by 90 basis points year-over-year to 71.7%, primarily impacted by higher manufacturing costs and 70 basis points of pricing erosion, partially offset by favorable product mix. |
Signal API · MCP
Track Zimmer Biomet with the Signal API
One POST /v1/companies/enrich call with zimmerbiomet.com returns Zimmer Biomet 10-Q signals (sec-10q), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"zimmerbiomet.com","signal_types":["sec-10q"],"limit":20}'Bulk data
Need this signal for 10,000+ companies?
Get a free sample file or a bulk feed (API, GCS push, flat file). The sample is real 10-Q Filings records, as a CSV.
Same industry
10-Q at related companies
Questions about Zimmer Biomet 10-Q
When did Zimmer Biomet file its latest 10-Q?
What did Zimmer Biomet disclose in its latest 10-Q?
What did Zimmer Biomet say on its recent earnings calls?
Where can I read Zimmer Biomet's 10-Q filing?
Page updated , the date of the newest row on this page.
Source. Quarterly reports (Form 10-Q) filed with the SEC. Every card links to the filing on EDGAR.
Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.
Data as of .